Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 197

1.

TLR7 Agonist Increases Responses Of HBV-Specific T Cells And Natural Killer Cells In Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C.

Gastroenterology. 2018 Jan 26. pii: S0016-5085(18)30072-6. doi: 10.1053/j.gastro.2018.01.030. [Epub ahead of print]

PMID:
29378197
2.

Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M.

PLoS One. 2018 Jan 2;13(1):e0190803. doi: 10.1371/journal.pone.0190803. eCollection 2018.

3.

Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.

Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, Biasiolo A, Abate ML, Plebani M, Smedile A, Bonino F, Pontisso P, Brunetto MR.

Cancer Biomark. 2017 Dec 15. doi: 10.3233/CBM-170551. [Epub ahead of print]

PMID:
29278878
4.

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.

Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ.

J Hepatol. 2018 Mar;68(3):431-440. doi: 10.1016/j.jhep.2017.10.027. Epub 2017 Dec 11.

PMID:
29104121
5.

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.

Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG.

PLoS One. 2017 Oct 4;12(10):e0185728. doi: 10.1371/journal.pone.0185728. eCollection 2017.

6.

Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.

Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S.

Liver Int. 2017 Sep 21. doi: 10.1111/liv.13596. [Epub ahead of print]

PMID:
28941023
7.

Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.

Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxì A, Vella S; PITER Collaborating Group.

Hepatology. 2017 Dec;66(6):1814-1825. doi: 10.1002/hep.29399. Epub 2017 Oct 30.

8.

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel.

Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party.

Dig Liver Dis. 2017 Jul;49(7):731-741. doi: 10.1016/j.dld.2017.03.027. Epub 2017 Apr 12.

PMID:
28456519
9.

Genome-Wide Comparison of Next-Generation Sequencing and qPCR Platforms for microRNA Profiling in Serum.

Blondal T, Brunetto MR, Cavallone D, Mikkelsen M, Thorsen M, Mang Y, Pinheiro H, Bonino F, Mouritzen P.

Methods Mol Biol. 2017;1580:21-44. doi: 10.1007/978-1-4939-6866-4_3.

PMID:
28439824
10.

Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.

Oliveri F, Surace L, Cavallone D, Colombatto P, Ricco G, Salvati N, Coco B, Romagnoli V, Gattai R, Salvati A, Moriconi F, Yuan Q, Bonino F, Brunetto MR.

Liver Int. 2017 Nov;37(11):1622-1631. doi: 10.1111/liv.13416. Epub 2017 Apr 18.

PMID:
28296013
11.

Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M.

PLoS One. 2017 Feb 28;12(2):e0172159. doi: 10.1371/journal.pone.0172159. eCollection 2017. Erratum in: PLoS One. 2018 Jan 2;13(1):e0190803.

12.

From current status to optimization of HCV treatment: Recommendations from an expert panel.

Craxì A, Perno CF, Viganò M, Ceccherini-Silberstein F, Petta S; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party.

Dig Liver Dis. 2016 Sep;48(9):995-1005. doi: 10.1016/j.dld.2016.06.004. Epub 2016 Jun 15.

PMID:
27388261
13.

New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases.

Ricco G, Bonino F, Lanza M, Scatena F, Alfieri CM, Messa P, Marchisio E, Mascolo G, Romanò L, Galli C, Li TC, Wakita T, Miyamura T, Brunetto MR.

Dig Liver Dis. 2016 May;48(5):536-541. doi: 10.1016/j.dld.2016.01.007. Epub 2016 Feb 10.

PMID:
26936342
14.

Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up.

Brouwer WP, Chan HL, Brunetto MR, Martinot-Peignoux M, Arends P, Cornberg M, Cherubini B, Thompson AJ, Liaw YF, Marcellin P, Janssen HL, Hansen BE; Good Practice in using HBsAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group).

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1481-1489.e5. doi: 10.1016/j.cgh.2016.01.019. Epub 2016 Feb 10.

PMID:
26872398
15.

A "systems medicine" approach to the study of non-alcoholic fatty liver disease.

Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F; Special Interest Group on Personalised Hepatology of the Italian Association for the Study of the Liver (AISF); Special Interest Group on Personalised Hepatology of Italian Association for Study of Liver AISF.

Dig Liver Dis. 2016 Mar;48(3):333-42. doi: 10.1016/j.dld.2015.10.027. Epub 2015 Nov 14. Review.

16.

Transmission FTIR derivative spectroscopy for estimation of furosemide in raw material and tablet dosage form.

Gallignani M, Rondón RA, Ovalles JF, Brunetto MR.

Acta Pharm Sin B. 2014 Oct;4(5):376-83. doi: 10.1016/j.apsb.2014.06.013. Epub 2014 Aug 8.

17.

Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.

Messori A, Brunetto MR, De Luca A, Zignego AL.

Dig Liver Dis. 2015 Nov;47(11):988-9. doi: 10.1016/j.dld.2015.06.012. Epub 2015 Jul 2. No abstract available.

PMID:
26205830
18.

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.

Yuan Q, Song LW, Cavallone D, Moriconi F, Cherubini B, Colombatto P, Oliveri F, Coco BA, Ricco G, Bonino F, Shih JW, Xia NS, Brunetto MR.

PLoS One. 2015 Jun 26;10(6):e0130209. doi: 10.1371/journal.pone.0130209. eCollection 2015.

19.

Reducing the price of new hepatitis C drugs in the Tuscany region of Italy.

Brunetto MR, De Luca A, Messori A, Zignego AL.

BMJ. 2015 Jun 24;350:h3363. doi: 10.1136/bmj.h3363. No abstract available.

PMID:
26108546
20.

A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C.

Iannazzo S, Colombatto P, Ricco G, Oliveri F, Bonino F, Brunetto MR.

Dig Liver Dis. 2015 Mar;47(3):249-54. doi: 10.1016/j.dld.2014.12.008. Epub 2014 Dec 18.

PMID:
25575431

Supplemental Content

Loading ...
Support Center